Wire News
LX211 highlighted as potential disease modifying therapy for noninfectious uveitis
LX211 (LUVENIQ; oral voclosporin) may become the first approved oral treatment capable of modifying the course of uveitis, otherwise inevitably associated with severe vision loss or substantial morbidity from steroid use. Phase 2/3 trial results highlight ...
Source:
DISCLAIMER
Wednesday, November 4, 2009